ESR1 and breast cancer: We treated a panel of TNBC and ER+ human breast cancer cell lines and several mouse ER-negative cell lines with the two antagonists and two RORγ agonists along with the PARP-1 inhibitors (Fig. 2e, Supplementary Fig. 2g) for comparison.